Syntara advances next-generation anti-fibrotic cream into Phase 1b trial

Syntara (ASX:SNT) has taken a significant step forward in the development of its next-generation topical anti-fibrotic therapy, announcing that its lead pan-lysyl oxidase inhibitor, SNT-9465, has completed a Phase 1a clinical trial and will now progress into a Phase 1b study in patients with hypertrophic scars. …